Researchers have cleared a major obstacle in the development of an HIV vaccine, proving in animal models that effective, yet short-lasting antibodies can be coaxed into multiplying as a fighting force against the virus.
"The reason we don't have a vaccine is because the immune system doesn't want to make the kind of antibodies that are needed to neutralize the virus," said co-senior author. "This study is proof of concept that we can engineer the immune system to create an environment where the right antibodies can be made."
The researchers built on years of successive studies that identified how and when broadly neutralizing antibodies (bnAbs) arise in people with HIV infections, and what prevents the antibodies from proliferating to negate the virus.
One problem lies in the immune system, which identifies some bnAbs as a danger and actively shuts down their production. Another problem is that the neutralizing antibodies require rare changes in their genetic make-up that are infrequently made during a crucial B-cell diversification process.
In the current study, the researchers traced those relevant mutations. Then they engineered an HIV protein, targeting a site called the V3 glycan region of the virus envelope, that preferentially bound to antibodies that have the unlikely but necessary mutations.
Using mouse models that express human neutralizing antibody precursors the researchers demonstrated that their immunogen could, indeed, coax a lineage of B-cells to undergo the improbable mutations that result in broadly neutralizing antibodies.
"Our ability to make mouse models that express human broadly neutralizing antibodies has provided powerful new model systems in which we can iteratively test experimental HIV vaccines", said the other co-senior author.
A second lineage of bnAbs -- binding to a different region of the virus's outer envelope called the CD4 binding site that has long been a focus of HIV research -- also went through improbable mutations. After the researchers reconstructed this antibody's history, they developed a second immunogen. Tested in non-human primates, it similarly selected for the necessary mutations, which led to the development of potent CD4 binding-site neutralizing antibodies.
"We have identified the mutations we need, which the immune system won't easily make, and can select for them in a vaccine that targets that mutation," the lead author said. "We have shown that we can overcome this major roadblock and can select for the right mutational changes in these bnAb precursors when they are starting to get better and better at neutralizing activity."
The researchers noted that ongoing studies are needed to identify additional antibodies to target as they identify and build immunogens that would constitute a vaccine.
"Without proper antigen selection it will take multiple decades of vaccination to elicit effective antibodies," the author said. "We can accelerate this timeline by designing sequential immunogens that select for the required combination of functional antibody mutations."
https://corporate.dukehealth.org/news-listing/immune-system-can-be-coaxed-selecting-key-antibodies-fight-hiv
https://science.sciencemag.org/content/366/6470/
Engineering better broadly neutralizing HIV antibodies
- 4,081 views
- Added
Edited
Latest News
Abusive drugs hijack natura…
By newseditor
Posted 23 Apr
Mechanism of action of the…
By newseditor
Posted 23 Apr
Role of fat in rare neurolo…
By newseditor
Posted 23 Apr
How protein synthesis in de…
By newseditor
Posted 22 Apr
Atlas of mRNA variants in d…
By newseditor
Posted 22 Apr
Other Top Stories
Ultrasound disruption of blood-brain barrier
Read more
Visualizing gene expression with MRI
Read more
Imaging retinal ganglion cells
Read more
A biosensor to detect tumors at early stages
Read more
First cell culture of live adult human neurons shows potential of b…
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
Exploiting pancreatic cance…
By newseditor
Posted 23 Apr
Structure of antiviral drug…
By newseditor
Posted 23 Apr
Type-I-interferon-responsiv…
By newseditor
Posted 23 Apr
Selenium, diabetes, and the…
By newseditor
Posted 23 Apr
Long-term neuropsychologica…
By newseditor
Posted 23 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar